Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dealing With Brexit: EMA Offers Firms Advice On More Thorny Questions

Executive Summary

The European Medicines Agency has updated its guidance on Brexit to offer companies more advice on the regulatory changes they will need to make in areas like transfers of MAs, rapporteurships and orphan designations, multi-country packs, and Article 58 opinions.

You may also be interested in...



Industry Told How To Categorize And Group Brexit-Related Manufacturing Changes

The EU group for coordinating drug approvals through the mutual recognition and decentralized procedures has developed a non-exhaustive list of scenarios that companies with manufacturing processes in the UK may face following Brexit, and explains how to address these through appropriate variation applications. 

EMA To Contact Sponsors Of Over 100 Drugs At Risk Of Shortage Post Brexit

The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.

EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses

The EMA is to further refocus on its core activities to help it deal with “higher than expected” staff losses due to its relocation to Amsterdam.

Topics

UsernamePublicRestriction

Register

PS123348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel